Clinical Trial: NCT02985957
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Bristol-Myers Squibb |
| Information Provided By: | Bristol-Myers Squibb |
| Last Update Posted: | 2025-12-22 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
Official Title
A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
Conditions
Prostate Cancer
Intervention / Treatment
- Biological: Nivolumab
- Biological: Ipilimumab
- Drug: Cabazitaxel
- Drug: Prednisone
Other Study ID Numbers
- CA209-650
- 2016-001928-54
- 2016
Start Date (Actual)
2017-03-26
Primary Completion Date (Actual)
2022-04-05
Study Completion Date (Actual)
2025-01-07
Enrollment (Actual)
351
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Bristol-Myers Squibb |
| Information Provided By: | Bristol-Myers Squibb |
| Last Update Posted: | 2025-12-22 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
Official Title
A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
Conditions
Prostate Cancer
Intervention / Treatment
- Biological: Nivolumab
- Biological: Ipilimumab
- Drug: Cabazitaxel
- Drug: Prednisone
Other Study ID Numbers
- CA209-650
- 2016-001928-54
- 2016
Start Date (Actual)
2017-03-26
Primary Completion Date (Actual)
2022-04-05
Study Completion Date (Actual)
2025-01-07
Enrollment (Actual)
351
Study Type
Interventional
Phase
Phase 2